- Home
- AMZN vs NVS Comparison
AMZN vs NVS Comparison
Compare AMZN & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZN | NVS |
|---|---|---|
| Founded | 1994 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6T | 293.9B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMZN | NVS |
|---|---|---|
| Price | $247.69 | $150.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 42 | 5 |
| Target Price | ★ $285.88 | $144.00 |
| AVG Volume (30 Days) | ★ 41.9M | 1.9M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | ★ 29.66 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $716,924,000,000.00 | N/A |
| Revenue This Year | $14.63 | $2.30 |
| Revenue Next Year | $11.81 | $5.27 |
| P/E Ratio | $88.61 | ★ $23.13 |
| Revenue Growth | ★ 12.38 | N/A |
| 52 Week Low | $196.00 | $112.34 |
| 52 Week High | $278.56 | $170.46 |
Technical Indicators
Market Signals| Indicator | AMZN | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 44.81 |
| Support Level | $225.71 | $149.49 |
| Resistance Level | $249.75 | $154.57 |
| Average True Range (ATR) | 7.36 | 2.21 |
| MACD | 1.71 | -0.57 |
| Stochastic Oscillator | 82.65 | 0.07 |
Price Performance
Historical ComparisonAbout AMZN Amazon.com Inc.
Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 74% of total, followed by Amazon Web Services (17%), and advertising services (9%). International segments constitute 22% of Amazon's total revenue, led by Germany, the United Kingdom, and Japan.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.